Precisely Shaped Acoustic Ablation Of Tumors Under 3D Ultrasound Image Guidance
Everette C Burdette, President/ceo
Acoustic Medsystems, Inc.
Grant 1R44CA134169-01A1 from National Cancer Institute, IRG: ZRG1
Abstract: Many recent studies have demonstrated the efficacy of interstitial ablative approaches for the treatment of hepatic tumors, including chemical ablation, cryoablation, and thermal ablation using energy sources like RF, laser, microwave, or focused ultrasound. Despite these promising results, current systems remain highly dependent on operator skill, and cannot treat many tumors because there is little control of the size and shape of the zone of necrosis, and no control over ablator trajectory within tissue. Remedying this problem requires advances in end-effector design, precise steering of the ablator device to the desired target location, and real- time monitoring of the zone of necrosis to ensure complete treatment. Intra-procedure ultrasound imaging provides perhaps the optimal and most readily available method for targeting, but simultaneous manual handling of the B-mode ultrasound (US) probe and the ablator device is a challenging task that is prone to significant errors in the hands of even the most experienced physicians. Tissue deformation and target motion make it extremely difficult to place the ablator device precisely into the target. Irregularly shaped target volumes typically require multiple insertions and several overlapping thermal lesions, which are even more challenging to accomplish in a precise and timely manner without causing excessive damage to surrounding normal tissues. In answer to these problems, we propose to develop an innovative method for accurate tracking and tool registration with respect to spatially-registered intaoperative US volumes without relying on an external tracking device. This three-dimensional ultrasound (3DUS) will be integrated with a flexible, snake-like lightweight and inexpensive robotic, called the Active Cannula (AC), to facilitate precise placement of a steerable ultrasound thermal ablator into the liver and to monitor the progress of tissue ablation with real-time 3D registered ultrasound. Recent developments of implantable or interstitial high-power ultrasound applicators have demonstrated extremely controllable and penetrating heating patterns which can be shaped and dynamically altered, providing an ideal mechanism for conformable thermal surgery. This controllability and penetration is highly desirable and would provide significant improvement over existing RF and microwave (MW) technology used for minimally invasive thermal ablation of liver tumors. However, to date the extensive evaluation of this minimally invasive technology has been limited mostly to in vivo canine prostates and moderately perfused tissues, and have not included the design iterations and thorough evaluations necessary for treating tumors within highly perfused liver tissue. The preliminary thermal data from thermal therapy of perfused liver (Section C) are encouraging. Ultrasound Interstitial Thermal Therapy (USITT) technology is promising and we will extend the technology to optimize its use for the treatment of hepatic tumors. The overall goal of this research and development is to provide a true closed-loop system for steering, placement, guidance, percutaneous delivery of conformal ablative therapy, and on-line monitoring of treatment. Hepatocellular carcinoma (HCC) is the most common type of common primary liver cancer and is associated with over one million cases diagnosed worldwide each year. In the United States specifically, HCC is being seen with increasing frequency, largely due to the incidence of known and clinically occult hepatitis C. Other primary malignancies are also on the rise in the U.S., including intrahepatic cholangiocarcinoma. Yet, metastatic disease from other sites to the liver is the most common hepatic malignancy overall in the U.S. Cancer of the colon and rectum account for the majority of these primary tumors which develop isolated liver metastases. While other primary tumors originating from gastrointestinal sites often develop hepatic metastases as well, tumors arising in other locations, including those of the breast and lung, also commonly develop hepatic metastases. For colorectal cancer specifically, approximately 20% of patients have clinically recognizable liver metastases at the time of their primary diagnosis. After resection of a primary colorectal cancer in the absence of apparent metastatic disease, approximately 50% of patients will subsequently manifest metastatic liver disease6. Given these figures, one can expect that at least 30,000 patients per year in the United States will develop metastatic colorectal cancer confined to the liver, each year. In selected patients, potentially curative therapies for primary and secondary liver cancer include surgical resection and in some cases liver transplantation. Unfortunately only a small percentage of patients are candidates for these treatments. Intraarterial approaches such as chemoembolization, while therapeutically useful in some cases, rarely achieves complete tumor destruction. For these reasons, an increasing interest has been focused on interstitial ablative approaches for the treatment of primary and metastatic liver cancer. Despite advances in the effectiveness of these therapies, precise targeting of the ablator device and monitoring of the zone of necrosis are still unsolved problems. The rationale for ablation therapy of liver tumors is evident. To begin, this approach often allows for greater preservation of uninvolved hepatic parenchyma, directing the treatment specifically to the tumor location. This feature is particularly beneficial for patients with hepatocellular carcinoma in the background of cirrhosis, where hepatic reserve is often limited. In cases of metastatic disease, tumors which are multiple, bilateral, centrally located, or in areas not technically resectable are potentially well suited for this approach. Additionally, localized ablative therapy may be applicable for some patients with isolated hepatic recurrence following liver resection, perhaps resulting in lower morbidity than repeat hepatic resection. Recent studies have demonstrated significant advantages of multi-transducer interstitial ultrasound applicators, most notably the capability to dynamically tailor the longitudinal and angular heating distribution which are important for conformable treatments and preserving critical non-targeted tissue. Recent studies have demonstrated significant advantages of multi-transducer interstitial ultrasound applicators, most notably the capability to dynamically tailor the longitudinal and angular heating distribution which are important for conformable treatments and preserving critical non-targeted tissue. Our goal is to develop a new system with integrated active cannula ultrasound ablator combination spatially- registered with 3D ultrasound image guidance that is widely affordable, including for community hospitals and satellite clinics. Furthermore, the proposed technology will be readily transferable to wide range of indications and usable with various ablative modalities
Project start date: 2008-08-01
Project end date: 2009-07-31
Sponsored Links Lab Supply Mall http://www.labsupplymall.com
Grants awarded to Everette C Burdette
HIGH-POWER INTERSTITIAL ULTRASOUND LIVER TUMOR ABLATION
Everette C Burdette, President
Burdette Medical Systems, Inc.
206 N. Randolph St., Suite 300
champaign, Il 618203979
Grant 1R43CA090552-01 from National Cancer Institute, IRG: ZRG1
Abstract: The objective of this proposed effort is to develop and evaluate high- powered interstitial ultrasound applicator technology and support systems specifically for thermal ablation of liver tumors. Recent investigations with interstitial ultrasound applicators in prostate and moderately perfused tissues have demonstrated extremely controllable and penetrating heating patterns which can be shaped and dynamically altered, providing an ideal mechanism for conformable thermal surgery. In order to extend this technology to liver ablation, the following Phase I studies are proposed (1) modify existing applicator technology for high- power devices required for liver tumor ablation; (2) perform theoretical investigations of new power application schemes and design parameters specific to ablating liver tumors; (3) develop and integrate system hardware and software for a controlling system prototype; and (4) perform in vivo liver experiments to evaluate applicators and support systems. The feasibility of controlled/conformal treatment of transversely and longitudinally larger tumor volumes in shorter time frames and with greater control will be assessed as compared to existing RF, Laser, and Microwave technology. The results and experience obtained from these studies will be applied to the conceptual development of clinical approaches and procedures in the treatment of liver tumors, with proposed implementation in the succeeding Phase II application. PROPOSED COMMERCIAL APPLICATIONS Minimally-invasive thermal ablation of liver tumors is a clinically viable technique which provides a less morbid alternative to surgery, and can be applied in patients whose disease is not surgically resectable or are a poor risk for open surgery. Current technology is limited to treating spherically shaped tumors <3cm effectively. High-power interstitial ultrasound technology has significant potential to treat larger tumors of complex shapes in controllable and faster manner, permitting more effective treatment for larger number of cases
Keywords: biomedical equipment development, interstitial, liver neoplasm, neoplasm /cancer thermotherapy, ultrasound therapy computer system design /evaluation swine
Project start date: 2000-09-11
Project end date: 2001-08-31
1R43CA090552-01 (2000): $99987
Quantitative C-arm Fluoroscopy - Prostate Brachytherapy
Everette C Burdette, President
Burdette Medical Systems, Inc.
206 N. Randolph St., Suite 300
champaign, Il 618203979
Grant 5R44CA099374-03 from National Cancer Institute, IRG: ZRG1
Abstract: Prostate cancer continues to be a significant health problem, both domestically and worldwide. Numerous studies have demonstrated the efficacy and safety of transperineal prostate brachytherapy in the therapy of prostate cancer. The success of brachytherapy chiefly depends on our ability to intra-operatively tailor the radiation dose to the patient´s individual anatomy. Thus the objective of this research is to design, develop, and clinically test a method for intra-operative localization of the implanted seeds in relation to the prostate, to allow for intra-operative dosimetric optimization and exit dosimetry. Brachytherapy is predominantly performed with transrectal ultrasound guidance, which provides adequate real-time visualization of soft tissue anatomy, but does not show the implanted seeds. To overcome this problem, we propose registration of ultrasound to intra-operative C-arm fluoroscopy, where the implanted seeds will be reconstructed from fluoroscopy and superimposed on ultrasound. In particular, we will (1) Design a system and workflow that is consistent with contemporary practice of prostate brachytherapy. (2) Develop optimized mathematical algorithms for reconstruction of seed implants from C-arm fluoroscopy images, spatial registration of fluoroscopy and ultrasound imaging. (3) Integrate the algorithms with an existing commercial prostate brachytherapy system and implant optimization methods. (4) Conduct Clinical System Performance Evaluation Trial on human patients. We have established the technical feasibility of this approach in a Phase-1 SBIR research grant. We are requesting Phase-2 support to develop a clinical-grade system and evaluate its technical performance on human patients. The resulting system will withstand the scrutiny of subsequent FDA approval and enter wide-spread clinical use via commercial dispersion
Project start date: 2003-07-01
Project end date: 2009-08-31
5R44CA099374-03 (2007): $520901
2R44CA099374-02A1 (2006): $534106
Precisely Shaped Acoustic Ablation Of Tumors Under 3D Ultrasound Image Guidance
Everette C Burdette, President/ceo
Acoustic Medsystems, Inc.
Grant 1R44CA134169-01A1 from National Cancer Institute, IRG: ZRG1
Abstract: Many recent studies have demonstrated the efficacy of interstitial ablative approaches for the treatment of hepatic tumors, including chemical ablation, cryoablation, and thermal ablation using energy sources like RF, laser, microwave, or focused ultrasound. Despite these promising results, current systems remain highly dependent on operator skill, and cannot treat many tumors because there is little control of the size and shape of the zone of necrosis, and no control over ablator trajectory within tissue. Remedying this problem requires advances in end-effector design, precise steering of the ablator device to the desired target location, and real- time monitoring of the zone of necrosis to ensure complete treatment. Intra-procedure ultrasound imaging provides perhaps the optimal and most readily available method for targeting, but simultaneous manual handling of the B-mode ultrasound (US) probe and the ablator device is a challenging task that is prone to significant errors in the hands of even the most experienced physicians. Tissue deformation and target motion make it extremely difficult to place the ablator device precisely into the target. Irregularly shaped target volumes typically require multiple insertions and several overlapping thermal lesions, which are even more challenging to accomplish in a precise and timely manner without causing excessive damage to surrounding normal tissues. In answer to these problems, we propose to develop an innovative method for accurate tracking and tool registration with respect to spatially-registered intaoperative US volumes without relying on an external tracking device. This three-dimensional ultrasound (3DUS) will be integrated with a flexible, snake-like lightweight and inexpensive robotic, called the Active Cannula (AC), to facilitate precise placement of a steerable ultrasound thermal ablator into the liver and to monitor the progress of tissue ablation with real-time 3D registered ultrasound. Recent developments of implantable or interstitial high-power ultrasound applicators have demonstrated extremely controllable and penetrating heating patterns which can be shaped and dynamically altered, providing an ideal mechanism for conformable thermal surgery. This controllability and penetration is highly desirable and would provide significant improvement over existing RF and microwave (MW) technology used for minimally invasive thermal ablation of liver tumors. However, to date the extensive evaluation of this minimally invasive technology has been limited mostly to in vivo canine prostates and moderately perfused tissues, and have not included the design iterations and thorough evaluations necessary for treating tumors within highly perfused liver tissue. The preliminary thermal data from thermal therapy of perfused liver (Section C) are encouraging. Ultrasound Interstitial Thermal Therapy (USITT) technology is promising and we will extend the technology to optimize its use for the treatment of hepatic tumors. The overall goal of this research and development is to provide a true closed-loop system for steering, placement, guidance, percutaneous delivery of conformal ablative therapy, and on-line monitoring of treatment. Hepatocellular carcinoma (HCC) is the most common type of common primary liver cancer and is associated with over one million cases diagnosed worldwide each year. In the United States specifically, HCC is being seen with increasing frequency, largely due to the incidence of known and clinically occult hepatitis C. Other primary malignancies are also on the rise in the U.S., including intrahepatic cholangiocarcinoma. Yet, metastatic disease from other sites to the liver is the most common hepatic malignancy overall in the U.S. Cancer of the colon and rectum account for the majority of these primary tumors which develop isolated liver metastases. While other primary tumors originating from gastrointestinal sites often develop hepatic metastases as well, tumors arising in other locations, including those of the breast and lung, also commonly develop hepatic metastases. For colorectal cancer specifically, approximately 20% of patients have clinically recognizable liver metastases at the time of their primary diagnosis. After resection of a primary colorectal cancer in the absence of apparent metastatic disease, approximately 50% of patients will subsequently manifest metastatic liver disease6. Given these figures, one can expect that at least 30,000 patients per year in the United States will develop metastatic colorectal cancer confined to the liver, each year. In selected patients, potentially curative therapies for primary and secondary liver cancer include surgical resection and in some cases liver transplantation. Unfortunately only a small percentage of patients are candidates for these treatments. Intraarterial approaches such as chemoembolization, while therapeutically useful in some cases, rarely achieves complete tumor destruction. For these reasons, an increasing interest has been focused on interstitial ablative approaches for the treatment of primary and metastatic liver cancer. Despite advances in the effectiveness of these therapies, precise targeting of the ablator device and monitoring of the zone of necrosis are still unsolved problems. The rationale for ablation therapy of liver tumors is evident. To begin, this approach often allows for greater preservation of uninvolved hepatic parenchyma, directing the treatment specifically to the tumor location. This feature is particularly beneficial for patients with hepatocellular carcinoma in the background of cirrhosis, where hepatic reserve is often limited. In cases of metastatic disease, tumors which are multiple, bilateral, centrally located, or in areas not technically resectable are potentially well suited for this approach. Additionally, localized ablative therapy may be applicable for some patients with isolated hepatic recurrence following liver resection, perhaps resulting in lower morbidity than repeat hepatic resection. Recent studies have demonstrated significant advantages of multi-transducer interstitial ultrasound applicators, most notably the capability to dynamically tailor the longitudinal and angular heating distribution which are important for conformable treatments and preserving critical non-targeted tissue. Recent studies have demonstrated significant advantages of multi-transducer interstitial ultrasound applicators, most notably the capability to dynamically tailor the longitudinal and angular heating distribution which are important for conformable treatments and preserving critical non-targeted tissue. Our goal is to develop a new system with integrated active cannula ultrasound ablator combination spatially- registered with 3D ultrasound image guidance that is widely affordable, including for community hospitals and satellite clinics. Furthermore, the proposed technology will be readily transferable to wide range of indications and usable with various ablative modalities
Project start date: 2008-08-01
Project end date: 2009-07-31
Ultrasound Ablation Of Bone Cancer Under CT Fluoroscopy
Everette C Burdette, President
Acoustic Medsystems, Inc. 206 N Randolph St, Ste 300 Champaign, Il 618203979
Grant 5R43CA112852-02 from National Cancer Institute, IRG: ZRG1
Abstract: Bone cancer and multiple myeloma affects over 600,000 people every year in the United States and causes progressive bone destruction that results in pain, fractures, and the inability to walk. The hypothesis of the proposal is that thermal ablation with high intensity interstitial ultrasound (HIIU) is efficacious in management of metastatic bone cancer. We propose to develop a mechanism to perform minimally invasive conformal bone ablation under combined computer tomography (CT) and CT fluoroscopy (CTF) guidance. We will prove that this method provides a consistent, reliable, and safe treatment option in a simple and cost-efficient manner. We propose classic medical technology development accomplished in two steps first the development of appropriate core technology, and then the evaluation of that in a Phase-1 clinical trial. The deliverables of the program will be (1) an advanced prototype of an integrated medical device that is ready for regulatory approval and subsequent commercial introduction, (2) clinical methodology for the use of this device to treat metastatic spine cancer. In particular, we will apply acoustic ablative needles to be inserted percutaneously into the bone near the target. Phase-1 research will establish the feasibility of safe and accurate percutaneous HIIU needle placement and ablation under real-time quantitative CT/CTF guidance. Specific aims are as follows Aim-1 Image Guidance Develop methodology, hardware, and software components for sterotactic image guidance of the ablator device and intra-operative optimization of the ablation. Aim-2 HIIU Applicator Package an acoustic ablator catheter in a needle for percutaneous introduction to bony tissues, compliant to the guidance method developed in Aim-1. Aim-3 Animal Studies Perform feasibility studies in ex-vivo and in-vivo animal models with the system developed in Aims 1 and 2.
Keywords: biomedical equipment development, bone neoplasm, image guided surgery /therapy, metastasis, neoplasm /cancer therapy, neoplasm /cancer thermotherapy, spine disorder, ultrasound therapy, computed axial tomography, fluoroscopy, nonhuman therapy evaluation, therapy design /development, bioimaging /biomedical imaging, laboratory rabbit
Project start date: 2005-09-21
Project end date: 2008-08-31
5R43CA112852-02 (2006): $183379
1R43CA112852-01 (2005): $183418
REAL TIME 3 DIMENSIONAL BRACHYTHERAPY GUIDANCE SYSTEM
Everette C Burdette, President
Burdette Medical Systems, Inc.
206 N. Randolph St., Suite 300
champaign, Il 618203979
Grant 5R44CA072414-03 from National Cancer Institute, IRG: ZRG7
Abstract: Adapted from Applicant´s ) s proposed a technique for continuing development of a real-time, three dimensional (3-D) ultrasound based visualization system for in-OR dose planning, real-time guidance of radioactive implants or in-OR post-implant assessment for treating prostate cancer. The system would include a real-time 3-D endorectal imaging probe and supporting 2-D, 3-D and virtual reality visualization interfaces. Present techniques using transrectal ultrasound guidance for brachytherapy are difficult to implement and often result in unacceptable rates of complications. The aim of the proposed technique is to consolidate the total implant procedure, reduce complication rates and improve local control by optimization of seed implantation during ultrasound-guided brachytherapy. PROPOSED COMMERCIAL APPLICATION NOT AVAILABLE
Keywords: biomedical equipment development, endoscopy, neoplasm /cancer radionuclide therapy, radiation therapy dosage, ultrasound scanning computer simulation, rectum /anus bioimaging /biomedical imaging, phantom model
Project start date: 1997-09-05
Project end date: 2001-06-30
5R44CA072414-03 (2000): $302560
C-arm Fluoroscopy For Prostate Brachytherapy
Everette C Burdette, President
Burdette Medical Systems, Inc. 206 N. Randolph St., Suite 300 Champaign, Il 618203979
Grant 1R43CA099374-01 from National Cancer Institute, IRG: ZRG1
Abstract: A technique is proposed for the development of an intraoperative, 3-dimensional registration of C-arm fluoroscopic images with spatially-registered ultrasound visualization and implant guidance of radioactive implants and on-line implant assessment during the procedure for treatment of prostate cancer. With present techniques using transrectal ultrasound guidance for brachytherapy, intra-operative localization of implanted seeds with respect to soft tissue anatomy is still an unsolved problem. Ultrasound (US) images provide satisfactory differentiation of relevant soft issue, but implanted brachytherapy seeds cannot be clearly identified in the US images. Currently sixty percent of the practitioners use intra-operative C-arm fluoroscopy as a qualitative check of the implants. While seeds can be accurately localized in X-ray, projected transluminal images do not reveal soft tissue anatomy. Hence, there is a standing clinical need to couple relevant information from C-arm with the US-guided delivery system, in a safe, robust, and cost-efficient manner. The goal of the proposed work is to implement intra-operative dosimetric quality assurance in transrectal US-guided prostate brachytherapy with the use of C-arm X-ray fluoroscopy. The specific objective of this program is to incorporate spatial location of implanted seeds determined from C-arm X-ray fluoroscopy images with soft tissue anatomy determined from ultrasound images. This will enable the actual dose distribution to be compared to the dose pre-plan and assessed while the implant process is underway. Thus, immediate therapeutic intervention would be possible to correct for any "cold" regions or minimize "hot" regions near critical structures and exactly "match" the optimal source placement within the treatment volume. The outcome of this research could be of immediate benefit in the treatment of prostate cancer. It would provide the ability to visualize in real time the placement of implants, providing implants which reflect optimal dosimetry. A large group of patients with early-stage disease are candidates.
Keywords: computer assisted patient care, computer program /software, fluoroscopy, neoplasm /cancer radionuclide therapy, prostate neoplasm, radiation dosage, radionuclide implant, technology /technique development, ultrasound imaging /scanning, bioimaging /biomedical imaging, biomedical automation, time resolved data, X ray, medical implant science, phantom model, radionuclide imaging /scanning
Project start date: 2003-07-01
Project end date: 2004-06-30
1R43CA099374-01 (2003): $166293
REAL-TIME ROBOTIC IMAGE-GUIDED PROSTATE BRACHYTHERAPY
Everette C Burdette, President
Burdette Medical Systems, Inc. 206 N. Randolph St., Suite 300 Champaign, Il 618203979
Grant 5R44CA088139-04 from National Cancer Institute, IRG: ZCA1
Abstract: A technique is proposed for the development of a real-time, 3- dimensional ultrasound-based visualization and implant system with robotic augmentation for intraoperative dose planning, real-time robotic guidance of radioactive implants and on-line implant assessment during the procedure for treatment of prostate cancer. This new system includes a real-time 3-dimensional endorectal imaging probe and supporting visualization interfaces coupled with robotic insertion of needles/sources in exact concurrence with optional dosimetry plan. Present techniques using transrectal ultrasound guidance for brachytherapy are difficult to implement and often result in unacceptable rates of complication. The aim of the proposed technique is to consolidate the total implant procedure, reduce Complication rates and improve local control by linking real-time intraoperative dosimetry with robotic-assisted source implantation during 3D ultrasound-guided brachytherapy. The primary objective of Phase I is to establish feasibility of robotic needle/seed implantation in phantoms and determine achievable levels of accuracy. PROPOSED COMMERCIAL APPLICATIONS The outcome of this research could be of immediate benefit in the treatment of prostate cancer using higher dose radiation with more accurate localization and fewer toxicities1less morbidity. It would provide the ability to visualize in real time the 3D prostate volume during robotic placement of implants, providing implants which reflect optimal dosimetry even in the hands of less experienced clinicians. A large group of patients with early-stage disease are candidates, including patients which would have normally been excluded because of public arch interference.
Keywords: image guided surgery /therapy, imaging /visualization /scanning, neoplasm /cancer radionuclide therapy, neoplasm /cancer surgery, prostate neoplasm, robotics, ultrasound imaging /scanning, radionuclide implant, bioimaging /biomedical imaging, human subject, phantom model
Project start date: 2000-09-13
Project end date: 2004-08-31
5R44CA088139-04 (2003): $182639
4R44CA088139-02 (2001): $422326
1R44CA088139-01 (2000): $131340
REAL TIME 3-DIMENSIONAL BRACHYTHERAPY GUIDANCE SYSTEM
Everette C Burdette, President
Burdette Medical Systems, Inc. 206 N. Randolph St., Suite 300 Champaign, Il 618203979
Grant 1R43CA072414-01A1 from National Cancer Institute, IRG: ZRG7
Abstract: A technique is proposed for the development of a real-time, 3- dimensional ultrasound-based visualization system for guidance of radioactive implants for treating prostate cancer. The system includes a real-time 3 dimensional imaging array and supporting 2D, 3D, and virtual reality visualization interfaces. Present techniques using transrectal ultrasound guidance for brachytherapy result in unacceptable rates of complication. The aim of the proposed technique is to reduce the complication rates and improve the local control rates by optimizing the visualization of seed implantation during ultrasound-guided brachytherapy. PROPOSED COMMERCIAL APPLICATION The outcome of this research could be of immediate benefit in the treatment of prostate cancer using higher dose radiation with more accurate localization and fewer toxicities/less morbidity. It would provide the ability to "see through" the 3D prostate volume while placing implants A large group of patients with localized disease or who are poor surgical risks or who do not desire open surgery are candidates.
Keywords: computer program /software, computer system design /evaluation, image processing, neoplasm /cancer radionuclide therapy, prostate neoplasm, time resolved data, ultrasound scanning, biomedical equipment development, clinical biomedical equipment, digital imaging, method development, radionuclide implant, phantom model
Project start date: 1997-09-05
Project end date: 1998-02-28
1R43CA072414-01A1 (1997): $99924
ULTRASOUND TECHNIQUE FOR PROSTATE THERMAL THERAPY
Everette C Burdette, President
Acoustic Medical Systems, Llc
1214 Foothill Dr
champaign, Il 61821
Grant 2R44DK051939-02 from National Institute Of Diabetes And Digestive And Kidney Diseases, IRG: ZRG7
Abstract: A system and technique for highly controlled thermal and/or ablative therapy of the prostate is proposed. Transurethral and miniature implantable ultrasound therapy applicators, with associated treatment planning and control systems are used to achieve optimal therapy delivery within the prostate gland. Acoustic field shaping and treatment planning are used to achieve treatment of the entire gland, or subregions of the gland. This approach provides for preferential treatment of cancers originating in the peripheral zone, yet can be optimized for disease originating in other zones. The appropriate combinations and positions of probes localize controllable and dynamically adjustable treatment zones. The overall objective is to develop minimally invasive techniques using a combination of transrectal and 2 to 3 miniature ultrasound needle probes for efficacious therapy while sparing the rectum, bladder, and other normal critical tissue structures. PROPOSED COMMERCIAL APPLICATIONS The outcome of this research could be of immediate benefit in the treatment of prostate cancer with fewer toxicities and morbidity. A large number of eligible patients exists, including those who recur after radiation, those who have extracapsular extension noted following radical prostatectomy, and those who cannot tolerate or select not to have open surgery
Keywords: biomedical equipment development, neoplasm /cancer thermotherapy, prostate neoplasm, ultrasound therapy clinical biomedical equipment, computer program /software, computer simulation, dosage, method development clinical research, dog, human subject
Project start date: 1996-09-30
Project end date: 2000-08-31
2R44DK051939-02 (1998): $464329
1R43DK051939-01 (1996): $99953
Related Publications
Robotic assistance for ultrasound-guided prostate brachytherapy. Med Image Anal. 2008 Oct; 12( 5): 535-45. Epub 2008 Jun 18. PMID: 18650122 Three-dimensional ultrasound-guided robotic needle placement: an experimental evaluation. Int J Med Robot. 2008 Jun; 4( 2): 180-91. PMID: 18433079 Robotically assisted prostate brachytherapy with transrectal ultrasound guidance--Phantom experiments. Brachytherapy. 2006 Jan-Mar; 5( 1): 14-26. PMID: 16563993